Houston, United States
PHIOGEN is a cutting-edge biotechnology enterprise emerging from the hallowed halls of Baylor College of Medicine. Operating out of its state-of-the-art lab in Helix Park, part of the Texas Medical Center, the world’s largest medical complex, this preclinical-stage company is disrupting the infectious disease sector with its innovative phage platform.
The primary focus of PHIOGEN lies in the development of dual-function bacteriophages. These engineered biological agents are designed not just to eliminate drug-resistant bacterial pathogens, but also to encourage the body's protective immunity. By leveraging proprietary technologies, including advanced screening and human-relevant models, PHIOGEN seeks to redefine the landscape of bacterial infection treatment, particularly where traditional antibiotics prove ineffective.
As the company progresses its pipeline of targeted phage therapies, it presents a promising investment opportunity for those aiming to bolster the medical biotechnology sector and combat a growing global challenge: antibiotic resistance.
